Sign in →

Test Code Ren Cancer Renal Cancer Panel (18 genes)

Performing Laboratory

BioReference-GeneDx

Methodology

Exon Array CGH, Next-gen Sequencing

 

Genes:

 BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL

Reference Values

See Report

 

 

Physician Office Specimen Requirements

Container/Tube:  Lavender top tube

Specimen:  2 - 5 mL Whole Blood

Transport Temperature: Room Temperature

 

Note:   Test requires indication for testing and family history submitted  with specimen

Computer Interface Code

PDM #  1659884

Useful For

  • 1) The family history is suggestive of a predisposition to renal cancer. Although VHL, MET, FLCN, FH, TSC1 and TSC2 are the genes that are the most often associated with classic forms of hereditary renal cancer, there are several other genes that cause an increased risk of renal cancer. The OncoGeneDx Renal Cancer panel includes analysis of these genes as well as 12 other genes affecting renal cancer risk. Thus, the OncoGeneDx Renal Cancer panel offers increased clinical sensitivity compared to testing only for the most commonly associated genes. Furthermore, panel testing is more cost effective than stepwise genetic testing (for example, ordering VHL testing followed by additional genetic testing, if negative).
  • 2) The differential diagnosis includes various hereditary cancer syndromes. For example, if the family history consists of multiple types of cancer, such as renal cancer in addition to pancreatic cancer, this may be associated with a cancer syndrome such as VHL or Lynch syndrome.
  • 3) Genetic testing has already been ordered due to a family history suggestive of a hereditary cancer predisposition and all results have been negative. OncoGeneDx Renal Cancer Panel includes genes whose role in cancer predisposition has been described recently in addition to genes associated with classic hereditary cancer syndromes.

CPT Code(s)

81403

81404

81405

81406

81407